Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.
作者信息
Albala David M
机构信息
Associated Medical ProfessionalsSyracuse, NY.
出版信息
Rev Urol. 2017;19(3):200-202. doi: 10.3909/riu193PracticeProfile.
Abstract
摘要
相似文献
1
Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.
Rev Urol. 2017;19(3):200-202. doi: 10.3909/riu193PracticeProfile.
2
ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.
Carcinogenesis. 2012 Mar;33(3):572-80. doi: 10.1093/carcin/bgs007. Epub 2012 Jan 9.
3
Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.
BMC Cancer. 2019 May 31;19(1):524. doi: 10.1186/s12885-019-5729-7.
4
Current perspectives on bone metastases in castrate-resistant prostate cancer.
Cancer Metastasis Rev. 2018 Mar;37(1):189-196. doi: 10.1007/s10555-017-9719-4.
5
Atg7 cooperates with Pten loss to drive prostate cancer tumor growth.
Genes Dev. 2016 Feb 15;30(4):399-407. doi: 10.1101/gad.274134.115.
6
Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer.
World J Clin Oncol. 2020 Jul 24;11(7):450-463. doi: 10.5306/wjco.v11.i7.450.
7
Potential role of rituximab in metastatic castrate-resistant prostate cancer.
J Oncol Pharm Pract. 2019 Sep;25(6):1509-1511. doi: 10.1177/1078155218790338. Epub 2018 Aug 9.
8
Complete PSA Response Following Stereotactic Ablative Radiotherapy for a Bony Metastasis in the Setting of Castrate-Resistant Prostate Cancer.
Cureus. 2015 Oct 26;7(10):e365. doi: 10.7759/cureus.365.
9
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8 T-cells Derived from Patients with Metastatic Castrate-resistant Disease.
Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21.
10
Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer.
Hong Kong Med J. 2013 Jun;19(3):237-41. doi: 10.12809/hkmj133804. Epub 2013 Apr 3.
引用本文的文献
1
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer.
Endocr Relat Cancer. 2025 May 29;32(6). doi: 10.1530/ERC-24-0188. Print 2025 Jun 1.
2
Incorporating Structured and Unstructured Data Sources to Identify and Characterize Hereditary Cancer Testing Among Veterans With Metastatic Castration-Resistant Prostate Cancer.
JCO Clin Cancer Inform. 2025 Feb;9:e2400189. doi: 10.1200/CCI-24-00189. Epub 2025 Feb 10.
3
Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach.
Cancers (Basel). 2024 Jan 23;16(3):482. doi: 10.3390/cancers16030482.
4
Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines.
Cell Death Dis. 2023 May 9;14(5):317. doi: 10.1038/s41419-023-05818-9.
5
Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.
Cancer Med. 2023 Mar;12(5):6040-6055. doi: 10.1002/cam4.5313. Epub 2022 Oct 13.
6
Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression.
Cancer Imaging. 2022 Jul 14;22(1):34. doi: 10.1186/s40644-022-00469-z.
7
Imaging of Oligometastatic Disease.
Cancers (Basel). 2022 Mar 10;14(6):1427. doi: 10.3390/cancers14061427.
8
HGK promotes metastatic dissemination in prostate cancer.
Sci Rep. 2021 Jun 10;11(1):12287. doi: 10.1038/s41598-021-91292-2.
9
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):680-688. doi: 10.1038/s41391-020-0236-0. Epub 2020 May 13.
本文引用的文献
1
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).
Urology. 2017 Jun;104:150-159. doi: 10.1016/j.urology.2016.12.033. Epub 2017 Mar 14.
2
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Cancer. 2017 Jun 15;123(12):2303-2311. doi: 10.1002/cncr.30587. Epub 2017 Feb 7.
3
Sequencing of agents in castration-resistant prostate cancer.
Lancet Oncol. 2015 Jun;16(6):e279-92. doi: 10.1016/S1470-2045(15)70033-1. Epub 2015 May 27.
4
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Lancet Oncol. 2015 May;16(5):509-21. doi: 10.1016/S1470-2045(15)70113-0. Epub 2015 Apr 14.
5
Alpha emitter radium-223 and survival in metastatic prostate cancer.
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
6
The changing landscape in the treatment of metastatic castration-resistant prostate cancer.
Ther Adv Med Oncol. 2013 Jan;5(1):25-40. doi: 10.1177/1758834012458137.
7
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
Zotero 插件